JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Ascendis Pharma A-S ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

201.69 0.56

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

200.56

Max

202.41

Pagrindiniai rodikliai

By Trading Economics

Pajamos

56M

-39M

Pardavimai

57M

158M

Pelno marža

-24.585

Darbuotojai

1,017

EBITDA

51M

2.3M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+26.88% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-13

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.6B

13B

Ankstesnė atidarymo kaina

201.13

Ankstesnė uždarymo kaina

201.69

Naujienos nuotaikos

By Acuity

50%

50%

147 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-24 18:41; UTC

Uždarbis

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

2025-10-24 18:31; UTC

Uždarbis

Correction to Procter & Gamble to Focus on Innovation

2025-10-24 16:25; UTC

Pagrindinės rinkos jėgos

Obook Shares Rise, Company Secures New Money Transmitter Licenses

2025-10-24 21:24; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-24 21:24; UTC

Rinkos pokalbiai

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

2025-10-24 21:07; UTC

Uždarbis

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

2025-10-24 20:58; UTC

Uždarbis

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

2025-10-24 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-10-24 20:40; UTC

Uždarbis

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

2025-10-24 20:24; UTC

Uždarbis

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025-10-24 20:23; UTC

Uždarbis

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025-10-24 20:13; UTC

Uždarbis

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025-10-24 20:07; UTC

Rinkos pokalbiai

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

2025-10-24 19:40; UTC

Rinkos pokalbiai

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

2025-10-24 19:35; UTC

Rinkos pokalbiai

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

2025-10-24 19:33; UTC

Uždarbis

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

2025-10-24 19:29; UTC

Rinkos pokalbiai

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

2025-10-24 18:52; UTC

Uždarbis

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025-10-24 18:41; UTC

Uždarbis

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025-10-24 18:03; UTC

Uždarbis

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

2025-10-24 18:02; UTC

Uždarbis

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

2025-10-24 18:00; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

2025-10-24 16:57; UTC

Uždarbis

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

2025-10-24 16:54; UTC

Rinkos pokalbiai

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

2025-10-24 16:44; UTC

Rinkos pokalbiai
Uždarbis

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

2025-10-24 16:39; UTC

Rinkos pokalbiai
Uždarbis

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

2025-10-24 16:33; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025-10-24 16:23; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025-10-24 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-10-24 16:07; UTC

Uždarbis

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Ascendis Pharma A-S ADR Prognozė

Kainos tikslas

By TipRanks

26.88% į viršų

12 mėnesių prognozė

Vidutinis 256.29 USD  26.88%

Aukščiausias 307 USD

Žemiausias 220 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ascendis Pharma A-S ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

17 ratings

17

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

157.66 / 167.29Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

147 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat